Resolution at Karessa Pharma’s extraordinary general meeting on 22 October 2019

An extraordinary general meeting of Karessa Pharma Holding AB (publ) was held on 22 October 2019, whereby the shareholders made the following resolutions. 

The extraordinary general meeting resolved, in accordance with the proposal from shareholders representing approximately 49.8 per cent of the shares and votes in the company, to elect Kristina Lidén Mascher and Neal Meacham as new members of the board of directors for the period until the end of the annual general meeting 2020.

The nature of this information requires Karessa Pharma Holding AB (publ.) to publish it as provided in the Nasdaq First North Growth Markets Rules for Issuers. This information was issued under the supervision of the contact persons below for publication on 22 October 2019 at 11:00 CEST.

For more information, please contact:
Mats Nilsson, VD Karessa Pharma Holding AB (publ)
Tel: +46-8-768 22 33
mats.nilsson@karessa.se

About Karessa Pharma Holding AB 
Karessa is a Swedish pharmaceutical company with the goal of developing products based on a patented drug delivery platform with direct absorption of active substances from the oral cavity to the bloodstream. For more information, visit karessa.se. Certified Advisor: FNCA Sweden AB, info@fnca.se, +46-8-528 00 399.

Tags: